Sarah Adenuga: Pharmacovigilance Research, Public Health Impact, and the Adenuga Name Across Medicine and Society

Introduction

Sarah Adenuga is a well known name in the field of pharmacovigilance, public health research and drug safety systems in Africa. The impact of her seminal research from 2019 to 2021 is still felt across the healthcare sector, the Government, and healthcare policy-making, particularly in the context of adverse drug reaction (ADR) reporting in resource-limited health systems.

Sarah Adenuga’s work continues to be of interest in 2026 due to its applicability to one of healthcare’s most pressing issues – medicines safety after they reach the patient. Concurrently, the Adenuga surname is found in several fields including medicine, media, politics and sports, thus, identification is paramount for researchers, students and health care practitioners seeking information on the name.

Who is Sarah Adenuga? Exploring B.A Adenuga’s Research Heritage

B.A. Adenuga is the most recognized clinical pharmacist and pharmacovigilance researcher with publications targeting the enhancement of drug safety systems in Africa. Her research mainly focuses on enhancing the reporting and monitoring of adverse drug reactions in healthcare settings and embedding pharmacovigilance into standard medical practice.

Her work attracted a global spotlight as there are major problems in the ability of many low and middle-income countries to track medication safety. Due to limited resources, staffing, and complex reporting systems, adverse reactions are underreported.

Specialties are:

• Pharmacovigilance system integration
• Reporting of adverse drug reactions (ADRs)
• Antiretroviral drug safety
• Public health policy
• Stakeholder engagement frameworks
• Healthcare system strengthening

Even as of 2026, there are still lots of healthcare institutions that are relying on Adenuga’s findings for practical solutions to medication monitoring without a drastic financial investment.

The most significant publications that shaped global drug safety

Sarah Adenuga’s research is significant and is represented by several publications in reputable medical and pharmaceutical journals.

Key Research Publications

One of the most important discoveries by Adenuga was the need to have ADR reporting systems embedded in the day-to-day activities of healthcare as opposed to being given as an administrative task.

Her research showed that systems that are simple, get feedback and have consistent training were more likely to have adverse reactions reported by healthcare workers.

The Pharmacovigilance Research carried out in Namibia by Sarah Adenuga.

Namibia has been an important case study for pharmacovigilance development in Africa with much of Adenuga’s most influential work taking place in the public healthcare system.

Issues that were identified in healthcare facilities.

Based on field research, Adenuga found that there are several obstacles in the effective reporting of ADRs:

• Poor reporting awareness among health professionals.
• Lack of feedback after reports were submitted
• The use of time in high-volume clinical environments
• Lack of integration with current patient care delivery systems
• Insufficient stakeholder involvement

The problems are not peculiar to Namibia, but rather are experienced by many health care systems in developing countries.

Solutions Proposed by Adenuga

Her research provided practical suggestions such as:

• Incorporating ADR reporting into normal clinical practice.
• Simplifying reporting procedures
• Increasing the training for healthcare workers.
• Establishing better communication links
• Creating strategies for building relationships with stakeholders

These recommendations have been helpful as they are based on changes that can be made rather than on huge infrastructure projects.

Most of these concepts are incorporated into wider WHO-AFRO pharmacovigilance capacity building activities and regional drug security programmes by 2026.

Antiretroviral Safety and HIV Treatment Research

A key research focus of Sarah Adenuga’s work is examining the safety characteristics of ART drugs for the treatment of HIV.

In 2019 she published in Drug Safety on adverse reactions related to:

• Atazanavir-based regimens
• Lopinavir-based regimens

These drugs are still vital part of the HIV treatment program from different healthcare systems.

The research gave healthcare providers valuable information on:

• Common adverse reactions
• Monitoring requirements
• Patient management strategies
• Risk-benefit assessments

This work is still applicable to the work of clinicians and policymakers overseeing treatment programs on the continent of Africa and elsewhere as treatment continues to grow in size and scope.

Why PV is more important than ever in 2026

In recent years there has been a growing recognition of the role of pharmacovigilance in the last decade.The role of pharmacovigilance has gained in importance significantly in the last decade.

Healthcare systems currently oversee:

• New HIV therapies
• Emerging vaccines
• Advanced biologic medications
• Pediatric antibiotic programs
• Treatments of complex chronic diseases

All new drugs coming into use must be continuously monitored for safety.

Sarah Adenuga’s research can enable healthcare systems to learn how to design and implement effective surveillance systems, even in the face of resource constraints.

The global health benefits of a robust pharmacovigilance programme

Effective pharmacovigilance helps:

• Be able to identify medicine safety concerns sooner
• Improve patient outcomes
• Minimise unnecessary adverse effects
• Provide data and information that enables informed policymaking
• Build confidence in health-care systems.

She highlights, above all else, the importance of cooperation between healthcare practitioners, patients, ministries of health, regulators and policy makers in her stakeholder engagement framework.

This comprehensive perspective is even more relevant to today’s public health planning.

In 2026, it will be an important public figure and will be disambiguated.

Since the name Adenuga is a common surname in Nigeria, there is a chance that the searcher may come across profiles of other people named Adenuga.

Dr. Adekoyejo Adenuga

A trusted doctor who specializes in pediatrics at Nuga Pediatrics Lenawee PLLC in Michigan.

Notable achievements include:

• Outstanding Patient Experience Award™ (2024, 2025, 2026)
• Excellent patient satisfaction scores
• Good reputation of pediatric health care.

Julie Adenuga

A well-known radio or TV personality who is known for:

• Beats 1 Radio hosting
• Forbes 30 Under 30 recognition
• Founder of Don’t Trust The Internet (DTTI)
• Interviews with all the big artists, from Jay-Z, Stormzy, to Billie Eilish.

Yemi Adenuga

An Irish politician and community campaigner who was recognized for:

• The Sheroes program
• Work with refugees and migrants.Support for refugees and migrants.
• This book examines the role of public service leadership in Ireland.

Ife Adenuga

An MLS Next Pro professional soccer player associated with Toronto FC II who caught onto the radar after finding a target in his maiden MLS Next Pro goal.

The reason why searchers should use the term ‘Sarah Adenuga pharmacovigilance’ or ‘B.A. Adenuga research’ to search for publications that are in the public health domain is illustrated in these examples.

The access to Sarah Adenuga’s work can be mediated by researchers.

The publications of Adenuga are available in several academic databases.

Best Research Sources

• PubMed
• Drug Safety Journal
• Basic Clinical Pharmacology & Toxicology
• Social and Administrative Pharmacy research.
• Exploratory Research in Clinical and Social Pharmacy” is a bi-monthly journal dedicated to the advancement of clinical and social pharmacy research.

When searching for “Adenuga BA” on PubMed, the basic publications related to pharmacovigilance that are published from 2019 to 2021 will likely be returned.

She has a number of associated topics such as:

• Namibia healthcare systems
• Drug safety monitoring
• Antiretroviral therapy
• ADR reporting systems
• Stakeholder engagement
• Resource-limited healthcare environments

There is at this day no widespread personal public profile available for B.A. Adenuga that is known except through journal correspondence information, as academic communication is normally done at that time.

Conclusion

Sarah Adenuga, or as she is known in the academic arena, B.A. Adenuga, continues to be a prominent contributor to Pharmacovigilance research and development and to public health policy. Her research into adverse drug reaction reporting, integration of healthcare systems, stakeholder engagement, and antiretroviral safety continues to inform healthcare systems in Africa and around the world.

The Adenuga name is known to great professionals in the medical, media, political and sports circles, but Sarah Adenuga’s legacy is best known in improving medication safety and ensuring robust healthcare systems. In 2026 and beyond, she has much to offer researchers, clinicians, policymakers, and public health leaders in practical approaches to pharmacovigilance in resource-limited settings, with her evidence-based frameworks relevant.